AstraZeneca in $15 Billion Talks to License Summit's Lung Cancer Drug Ivonescimab

Reuters7Month3According to Bloomberg, citing people familiar with the matter,Summit Therapeutics(Stock Code:SMMT.O) and AstraZeneca (stock code:AZN.L) are negotiating a deal worth up to150Negotiations on a cooperation agreement worth billions of dollars have been launched.

According to the potential cooperation framework, AstraZeneca may obtainSummitExperimental Lung Cancer Treatment DrugivonescimabAuthorization. This drug is currently in the research and development stage, and its therapeutic potential in the field of lung cancer has been widely recognized in the industry.

The Bloomberg report pointed out that the cooperation agreement might include an upfront payment of several hundred million US dollars, with additional payments to be made subsequently based on R&D milestones. Such"Down payment+Milestone"This transaction model is quite common in the biopharmaceuticals industry, providing early-stage funding support for innovative drug companies while reducing R&D risks for large pharmaceutical enterprises through phased payments.

As of the time of writing,SummitNo immediate response was made to media inquiries, while a spokesperson for AstraZeneca declined to comment. It is common practice for significant collaborations to remain confidential until officially announced, with both parties' cautious approach aligning with industry norms.